Navigation Links
DOR BioPharma Announces Publication Describing Results of Its,Multivalent Botulinum Toxin Vaccine BT-VACC

dministration of one of the serotype to rats results in significant levels of circulating antibodies as well as protection against toxin exposure.

About Botulinum Toxin

Botulinum toxin is an extremely potent neurotoxin of bacterial origin that inhibits peripheral nerve function, causing severe and often fatal descending flaccid paralysis. Natural botulism resulting from ingestion of toxin from contaminated food is very rare, but artificially, botulism also can result from bioterrorism and biowarfare. Because extremely small amounts can cause neurological effects, it is classified as a category A Biothreat by the CDC. The toxin can enter the body very efficiently through lung tissue and through the gastrointestinal tract, making the threat of purposeful food contamination a real possibility for use of the toxin as a biological weapon. Because the toxin rapidly enters target neural cells, exposure is difficult to treat with any available therapeutic regimen other than supportive care. In extremely minute quantities, botulinum toxin can be used therapeutically, as for the cosmetic use of Botox®, a commercial preparation of serotype A botulinum toxin, but the effects of the neurotoxin are extremely long lasting and paralytic at higher than therapeutic doses.

About Botulinum Toxin Vaccines

Vaccination is considered the best option to prevent neurological effects of toxin exposure. Because of the rarity of the natural disease, a vaccine would not be used in mass population immunization programs unless they were actually used or a significant threat. In that event, the vaccine would have to be made available for widespread dissemination for rapid and convenient vaccination of a large population. The only vaccine available is an experimental vaccine based on inactivation of a mixture of serotypes of the natural toxins that is given by injection, is not licensed by the FDA and cannot be used for widespread immunization. New multivalent vaccine
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
2. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
3. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
4. Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory Drugs
5. PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week
6. AVI BioPharma Reports Positive Pre-Clinical Influenza Data
7. Helix BioPharma Corp. Announces Positive Phase II Clinical Results with its Topical Interferon Alpha-2b
8. CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third Generation RIMA Antidepressant
9. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:11/30/2008)...ec. 1 Abnormalities in ...in children with autism spectrum disorder by using...y presented today at the annual meeting of the Rad..., "Using MEG, we can record the tiny magnetic fi...aid Timothy Roberts, Ph.D., vice chair of research...
(Date:11/26/2008)...information density, automation and intelligent cl...trasound to an all new level , , CHICAGO, I...Healthcare ( www.siemens.com/healthcare ) highli...Scanner (ABVS)(1), the world,s first multi-use, a...4th Scientific Assembly and Annual Meeting of the ...
(Date:11/25/2008)...FRANCISCO, Calif., Nov. 25 Proteol...nt of novel therapeutics that target,protein degr..., today,announced that data from two ongoing Phas...eloma will be presented at the upcoming 50th Annua...ASH). Carfilzomib is the first in a new class,of...
(Date:11/24/2008)... Ill., and OSAKA, Japan, Nov. 24 T...y-owned subsidiary, Takeda Global Research & D...t the Arthritis Advisory Committee of the U.S. Foo...he FDA approve febuxostat for the treatment of hy... to zero in favor of approval, with one panel memb...
Breaking Medicine Technology:Brain Waves Show Sound Processing Abnormalities in Autistic Children 2Brain Waves Show Sound Processing Abnormalities in Autistic Children 3Siemens Introduces New Standard of Care for Breast Ultrasound 2Siemens Introduces New Standard of Care for Breast Ultrasound 3Siemens Introduces New Standard of Care for Breast Ultrasound 4Siemens Introduces New Standard of Care for Breast Ultrasound 5Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 2Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 3Bad News to Bad Bugs 3A Northern Antibiotics Develops Novel Polymyxins With Reduced Toxicity 2567 1Bad News to Bad Bugs 3A Northern Antibiotics Develops Novel Polymyxins With Reduced Toxicity 2567 2SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen 28R 29 Versus Supportive Care in Patients With Myelodysplastic Synd 2565 1SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen 28R 29 Versus Supportive Care in Patients With Myelodysplastic Synd 2565 2SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen 28R 29 Versus Supportive Care in Patients With Myelodysplastic Synd 2565 3SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen 28R 29 Versus Supportive Care in Patients With Myelodysplastic Synd 2565 4Pressure Cycling Technology 28PCT 29 Results in a Higher Yield of Proteins and in the Extraction of Proteins Not Previously Identified in Cancer Str 2563 1Pressure Cycling Technology 28PCT 29 Results in a Higher Yield of Proteins and in the Extraction of Proteins Not Previously Identified in Cancer Str 2563 2Pressure Cycling Technology 28PCT 29 Results in a Higher Yield of Proteins and in the Extraction of Proteins Not Previously Identified in Cancer Str 2563 3 Great Doctors Produce Great Results 28Healthcare Underwriters Group Mutual of Ohio Pays A Cash Dividend 29 3A Healthcare Underwriters Group Mut 23009 1 Great Doctors Produce Great Results 28Healthcare Underwriters Group Mutual of Ohio Pays A Cash Dividend 29 3A Healthcare Underwriters Group Mut 23009 2
...NGELES & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ap...maceutical company focused on,the discovery and de...ay announced encouraging preclinical data of AV-41...nhibitor of EGFR/HER2 using,AVEO,s unique EGFR mut...he results from the preclinical study showed that ...
...r Presentation on April 17, 2007 at AACR, SAN DIEG...aceuticals, Inc. presented data from an in vitro s...promotes natural killer (NK),cell-mediated anti-tu...ysis of tumor cells and enhanced antibody-dependen...esentation at the Annual,Meeting of the American A...
Other Medicine Technology:AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer 2AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer 3AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer 4Anadys Reports Preclinical Data Showing ANA773 Promotes Anti-Tumor,Activity of Natural Killer Cells 2Anadys Reports Preclinical Data Showing ANA773 Promotes Anti-Tumor,Activity of Natural Killer Cells 3Anadys Reports Preclinical Data Showing ANA773 Promotes Anti-Tumor,Activity of Natural Killer Cells 4
(Date:12/2/2008)...irstCall/ -- Neuralstem Inc.,(NYSE Alternext US: ...ollaboration with the China Medical University &am...Neuralstem,s human spinal cord neural stem cell,t...phic Lateral Sclerosis (ALS,or Lou Gehrig,s disea...,investigator. , (Logo: http://www.newscom...
(Date:12/2/2008)...ia-FirstCall/ -- China Sky One Medical,Inc. ("Ch...CSKI ), a leading,fully integrated pharmaceutical...People,s Republic of China ("PRC"), announced toda...f Financial Officer and Secretary and will,also s...aces Yu-kun Zhang, who,had served as interim CFO ...
(Date:12/2/2008)...Call/ -- Mylan Inc. (NYSE: MYL ) today,announce...s Inc., have entered,into a settlement agreement ...p. and Novartis International AG related to Letroz...ara(R). , Mylan,s Vice Chairman and CEO Rob...ave reached this agreement, which demonstrates our...
(Date:12/2/2008)...ire/ -- In response to the commentary entitled "Co...ory Infections, and the Vitamin D Deficiency Epide...upplement experts, Nordic Naturals announced today... compromise to consumers and actually offer health...al Vitamin A. According to Karin Yien, MD, Nordic ...
Breaking Medicine News(10 mins):Health News:Neuralstem Collaborates with Hospital in Taiwan to Develop Additional ALS Stem Cell Clinical Trials 2Health News:China Sky One Medical, Inc. Appoints Yu-bo Hao as CFO 2Health News:China Sky One Medical, Inc. Appoints Yu-bo Hao as CFO 3Health News:Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity 2Health News:Nordic Naturals Offers Cod Liver Oil Solutions in Response to Recent Vitamin A and Vitamin D Controversy 2
...uta of the Salvation Healing Ministry, who is a se...rt on charges of swindling six people of Sh1.6 mil...le that they would be cured of HIV/AIDS through pr...te, Margaret Muigai, denied her bail since Central...
...acco by youngsters will cost their dear lives and ...people a year, which will greatly affect the count...me to over 250 million tobacco users and more than...ated diseases every year. But the most ominous sig...
...l carried out to treat diabetic nerve damage has s...vered by researchers// of the University of Manche...to trigger a particular gene responsible to preven...tic neuropathy. The positive preclinical results...
...spitals revealed falling standards of cleanliness .... Comparing to 56 percent people in 2002, only 52...y about 51 percent in 2003 said lavatories were ve.... Contradicting the above, the annual NHS patients...
Other Medicine News:Health News:Tobacco Consumption By Youths Will Hamper India’s Economic Growt 2Health News:New Gene Therapy Treats Diabetic Neuropathy 2
...ducts are offered as 1-piece or modular, in regula...ay be customized with handles of choice and other ...ts. Many standard patterns are available from Medi...ivery times. , Please Note: Individual instrumen...
...ducts are offered as 1-piece or modular, in regula...ay be customized with handles of choice and other ...ts. Many standard patterns are available from Medi...ivery times. , Please Note: Individual instrumen...
...ducts are offered as 1-piece or modular, in regula...ay be customized with handles of choice and other ...ts. Many standard patterns are available from Medi...ivery times. , Please Note: Individual instrumen...
The Featured Products are kept in stock at Mediflex and are offered as 1-piece or modular in regular or extra long lengths. All come equipped with insulation, flush ports, rotating shafts, ratchets (
Medicine Products: